Patient info Open main menu

Boston Multivitamins Oral Drops – Summary of Product Characteristics (SmPC) for healthcare professionals

Last updated: · Text from the MHRA, as of · About this document

The Summary of Product Characteristics (SmPC) is written for healthcare professionals. Patients will find plain advice in the patient information leaflet.

Contains active substance:

Summary of Product Characteristics (SmPC) - Boston Multivitamins oral drops

1 NAME OF THE MEDICINAL PRODUCT

Boston Multivitamins Oral Drops

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 0.6 ml contains:

Vitamin A Palmitate BP 5,000 units

Ergocalciferol (Vitamin D2) Ph Eur 400 units

Thiamine hydrochloride BP 1 mg

(Vitamin B1)

Riboflavin (Vitamin B2) BP 400 micrograms

Pyridoxine hydrochloride BP 500 micrograms

(Vitamin B6)

Ascorbic acid (Vitamin C) BP 50 mg

Nicotinamide BP 5 mg

Excipient(s):

This product contains Sucrose.

This product also contains E219 Sodium Methylhydroxybenzoate.

For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Oral Drops, Emulsion (Oral Drops)

Yellowish orange coloured liquid, slightly viscous.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

As a supplement for the prevention of vitamin deficiency states. As an aid to the maintenance of normal health and growth in infants and young children.

4.2 Posology and method of administration

Method of administration

To be administered by oral route.

Dose:

Infants from 6 weeks to one year : 0.3 ml daily (7 drops).

Older children, adults and elderly: 0.6 ml daily (14 drops) or as directed by the physician.

4.3 Contraindications

Hypersensitivity to any of the active substances or any of the excipients.

Contraindicated in hypercalcaemia.

Contraindicated in women who are (or may become) pregnant (see 4.6).

4.4 Special warnings and precautions for use

When multivitamin preparations are prescribed allowance must be made for vitamins from other sources.

No other preparations contain vitamin A should be taken with this preparation except under medical supervision.

Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Label will state:

Do not exceed the stated dose.

Keep out of the Reach and Sight of children.

Contains Sodium methylhydroxybenzoate (E219). May cause allergic reactions (possibly delayed).

Contains Sucrose: If you have been told by doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

4.5 Interaction with other medicinal products and other forms of interaction

Vitamin A

Neomycin: Absorption of Vitamin a possibly reduced by neomycin

Retinoids: Risk of hypervitaminosis A when vitamin A given with retinoids

Vitamin D:

Barbiturates, carbamazepine, phenytoin, primidone: Vitamin D requirements possibly increased when given with either of the listed medications.

Diuretics thiazide: Increased risk of hypercalacaemia when vitamin D given with thiazide and related diuretics.

4.6 Fertility, Pregnancy and lactation

In view of evidence suggesting that high levels of Vitamin A may cause birth defects, women who are (or may become) pregnant are advised not to take Vitamin A supplements (including tablets and fish-liver oil drops), except on the advice of a doctor or an antenatal clinic ( see section 4.3).

Vitamin D is secreted in breast milk and may cause hypercalcaemia in infants.

4.7 Effects on ability to drive and use machines

None known.

4.8 Undesirable effects

No undesirable effects due to the administration of Boston Multivitamins Oral Drops have been reported, and none can be expected if the dosage schedule is adhered to.

Excessive dose of Vitamins A and D can lead to hypervitaminosis

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

4.9 Overdose

Symptoms of Vitamin overdosage may include anorexia, nausea, vomiting, rough dry skin, polyuria, thirst, loss of hair, painful bones and joints, as well as raised plasma and urine calcium and phosphate concentration.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Multivitamins

ATC Code: A11A multivitamins combinations

5.2 Pharmacokinetic properties

None stated.

5.3 Preclinical safety data

Not available.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Sucrose

Polysorbate 80

Sodium hydroxide

Sodium methyl hydroxybenzoate (E219)

Deionized water

6.2 Incompatibilities

None known.

6.3 Shelf life

2 years.

6.4 Special precautions for storage

Store in dry place below 25°C.‘Keep bottle in the outer carton in order to protect from light’

6.5 Nature and contents of container

Type III amber glass bottles with a white HDPE/MDPE (High density or Medium density polyethylene) cap having LPDE droppler.

Pack size 25ml 2 bottles per carton

Pack size 25ml 1 bottle per carton

Pack size 10ml 1 bottle per carton

Pack size 50ml 1 bottle per carton

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

This medicine must not be used after the date (Exp) printed on the back. Any unused product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER

Boston Healthcare Limited

Unit 6, Navigation Court

Calder Park

Wakefield

West Yorkshire WF2 7BJ

United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 39974/0022

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

12/04/2011

10 DATE OF REVISION OF THE TEXT

13/08/2015

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 39974/0022

Last revision stated in the text: 13 August 2015 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Boston Multivitamins oral drops

Active substance Ergocalciferol
Pharmaceutical form Yellowish orange coloured liquid, slightly viscous.
Excipients Sucrose, Polysorbate 80, Sodium hydroxide, Sodium methyl hydroxybenzoate (E219), Deionized water
Shelf life 2 years.
Storage Store in dry place below 25°C.‘Keep bottle in the outer carton in order to protect from light’
Drug group (ATC) Multivitamins
Marketing authorisation PL 39974/0022 (first authorised 12 April 2011)
Marketing authorisation holder Boston Healthcare Limited

Sources: the MHRA product information (products.mhra.gov.uk). Contains public sector information licensed under the Open Government Licence v3.0.